Shares of Chemours (CC) tumbled 6.28% in after-hours trading on Tuesday following the release of the company's first-quarter 2025 earnings report, which presented a mixed picture of its financial performance.

The chemical company reported adjusted earnings per share (EPS) of $0.13, significantly below the analyst consensus estimate of $0.21. This earnings miss appears to be the primary driver behind the stock's sharp decline. Additionally, Chemours' adjusted EBITDA came in at $166 million, falling short of the expected $171.3 million.

Despite the disappointing bottom-line results, Chemours did manage to outperform on the top line. The company reported Q1 sales of $1,400 million, surpassing the analyst estimate of $1,352 million. This revenue beat, however, was not enough to offset investor concerns about the company's profitability.

Looking ahead, Chemours provided its outlook for the full year 2025, projecting adjusted EBITDA to be between $825 million and $950 million. The market's reaction suggests that investors may view this guidance as conservative or potentially indicative of ongoing challenges in the company's operating environment.

The after-hours plunge highlights the market's sensitivity to earnings misses, particularly in the current economic climate where investors are closely scrutinizing company performances. Chemours' ability to rebound from this setback will likely depend on its performance in the coming quarters and any strategic initiatives it may undertake to improve profitability.